AI could help clinicians detect valvular heart disease earlier and identify patients at higher risk of progression, a review suggests. The authors examined how AI could flag patients for further evaluation, make imaging measurements more consistent, and identify patients whose risk may be underestimated by conventional severity grading.
Detecting Valvular Heart Disease Earlier
Deep learning models applied to standard 12-lead electrocardiograms have identified patients with moderate or severe aortic stenosis. In one study, patients flagged by the model who had no aortic stenosis on a concurrent echocardiogram were more likely to develop the condition later. AI-guided point-of-care ultrasound has also helped operators without specialist training acquire diagnostic-quality cardiac images, expanding potential screening options in settings with limited access to echocardiography.
Measuring Valve Disease Severity With AI
Automated echocardiographic measurements are most established in aortic stenosis. In one study, AI measurements of peak aortic velocity, transvalvular gradient, and aortic valve area correlated strongly with expert measurements (r = 0.88–0.97). Researchers have also automated some measures of mitral regurgitation, including vena contracta width, while valve-specific measurements for aortic and tricuspid regurgitation remain less extensively validated.
The review also describes how AI can automate assessment of ventricular remodeling and myocardial fibrosis on cardiac MRI. AI-assisted cardiac CT can support planning for transcatheter valve procedures.
Can AI Improve the Timing of Valve Care?
Machine learning may help identify patients whose prognosis differs despite similar valve severity grades. In one aortic regurgitation study, a subgroup composed predominantly of women appeared to have less severe disease by conventional measures, yet had a mortality risk comparable to that of patients with overt ventricular dysfunction.
For clinicians, the next question is whether that additional risk information can improve decisions about follow-up, referral, or valve intervention. The review found that most studies of AI in valvular heart disease have yet to test those decisions prospectively. The authors called for studies that define what clinicians should do after an abnormal AI result and assess whether those actions improve patient outcomes.
Reference
Fakikh Y et al. AI in valvular heart disease: imaging, quantification, risk prediction, and potential clinical decision support. Methodist Debakey Cardiovasc J. 2026;22(5):6–19.